Oxymap has developed technology enabling ophthalmologists to evaluate the oxygen saturation in the retinal blood vessels. Retinal oximetry allows measurement of the underlying disturbance in important diseases such as diabetic retinopathy, glaucoma and retinal vascular occlusions. Oxymap opens up a completely new and better way of diagnosing and monitoring these diseases.

Current diagnostic and monitoring methods rely on subjective tests or the evaluation of structural changes caused by damage that has already occurred in the retina. Structural changes generally occur late in the disease process and the results of subjective tests tend to be highly variable. These issues lead to delayed treatment vision loss and high costs. Compared to the today’s best practice technologies, the Oxymap T1 allows more precise and objective measurements of the disease, which complement current methods and enable ophthalmologists to guide treatments in a more effective manner. Retinal oximetry has the potential to predict problems before they occur.

Retinal oximetry holds promise beyond ophthalmology as early research has demonstrated a link between disturbance in retinal oxygen saturation and neurological diseases (i.e., M.S., Alzheimer’s) as well as a strong correlation with systemic oxygen saturation levels.

The Oxymap T1 is a CE Marked medical device.